β2-Glycoprotein 1 Antibodies, IgG
Also known as: Anti-β2 Glycoprotein 1, Beta-2 Glycoprotein 1 Antibodies
Use
Assess the risk of thrombosis in patients who may be at risk for antiphospholipid syndrome (APS). This test should be used in conjunction with current traditional anticardiolipin and anticoagulant tests.1
Special Instructions
β2-Glycoprotein 1 is a plasma factor required for ACA binding, with β2-GP1-dependent binding frequently detected in patients with APS symptoms. All three isotypes of anti-β2-GP1 (IgG, IgM, and IgA) are associated with thrombosis. ACA that do not require β2-GP1 are usually transient and not clinically significant.
Limitations
Anti-β2-Glycoprotein 1 should not be used alone as a screening test for antiphospholipid syndrome. While anti-β2-GP1 assays may be more specific for APS than ACA, approximately 30% of patients tested for both will have discordant results, and anti-β2-GP1 can be useful in evaluating patients with positive ACA results not consistent with APS.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 16135-6
- 16135-6
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 15 days |
| Refrigerated | 15 days |
| Frozen | 15 days |
Other tests from different labs that may be relevant